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Introduction {#sec006}
============

Lower-middle-income countries account for over 75% of the 10.6 million annual deaths in children under five worldwide \[[@pone.0143729.ref001]\]. In Africa, the most frequent fatal outcomes stem from neonatal causes (26%), respiratory tract infections (21%), malaria (18%), diarrhea (16%) and HIV-infection (6%) \[[@pone.0143729.ref001]\]. Bacterial infections are often underreported among causes of child mortality in developing countries, the most frequently reported being upper respiratory tract infections. Bloodstream infections (BSI) are considered as a leading cause of severe bacterial infections in children. These severe sepses are challenging since the disease can progress rapidly to death if prompt effective antibiotic therapy is not undertaken. A few studies in Africa reported high case-fatality rate associated with BSI, mainly caused by Gram-negative bacteria, and being 2-fold higher than that of malaria (43.5% versus 20.2%) \[[@pone.0143729.ref002],[@pone.0143729.ref003]\].

BSI are also absent from the World Health Organization estimates of the most frequently reported causes of deaths in neonates which are preterm (28%), sepsis or pneumoniae (26%) and asphyxia (23%) \[[@pone.0143729.ref004]\]. However, a recent report estimated the incidence of possible severe neonatal bacterial infections of about 6.9 million of annual cases and showed that they were a major contributor to mortality. Indeed they could cause up to one third of the 2.9 million neonatal deaths reported in lower-middle-income countries (LMIC), which account for 99% of the annual worldwide neonatal deaths \[[@pone.0143729.ref004],[@pone.0143729.ref005]\].

The worldwide increase of extended-spectrum beta-lactamases produced by *Enterobacteriaceae* (ESBL-E) is worrisome in clinical practice since it may worsen the burden of severe sepsis of young infants in developing countries. Indeed, such highly resistant pathogens are usually isolated from healthcare-associated infections and are associated with poor outcomes \[[@pone.0143729.ref006]--[@pone.0143729.ref013]\]. The situation is even more alarming with the emergence of new mechanism of resistance reported in ESBL-E strains conferring resistance to carbapenems, which are drugs of last resort to treat ESBL-E infections \[[@pone.0143729.ref014]\].

Although previous studies already reported the existence of ESBL-E in several African countries, the extent of the ESBL-E epidemic, as well as its determinants and outcomes have been poorly evaluated until now. Based on a clinical study conducted in a large pediatric center in Dakar, Senegal, we aim to determine the epidemiological aspects and estimate the clinical burden of ESBL-E infections in young hospitalized infants.

Materials and Methods {#sec007}
=====================

Study design and population {#sec008}
---------------------------

Albert Royer Children's hospital is the referral tertiary-care teaching pediatric hospital in Dakar accounting for 5,000 admissions per year with 120 beds of neonatal, pediatric and surgical activity. A case-case-control study nested in a cohort was conducted including all patients admitted at hospitals during a two-year period (January 1, 2012 to December 31, 2013). Patients from whom an *Enterobacteriaceae* was recovered from a blood sample, drew in case of infection suspicion, were eligible to be included in the cohort study. Only hospital-acquired (HA) BSI caused by *Enterobacteriaceae* strains were considered for data analysis. Indeed, patients with a community-acquired and those with a BSI caused by a bacterial other than an *Enterobacteriaceae* were excluded of the study. The date of BSI onset was the date of collection of the first blood sample yielding an *Enterobacteriaceae* strain. If a bacterial strain was isolated on several occasions, only the first isolation was considered.

Cases were patients with a HA-BSI caused by an *Enterobacteriaceae* and included two subgroups of inpatients: those with ESBL-positive BSI and those with ESBL-negative BSI. Controls were patients who did not experience an infection during the study period and were randomly selected from the hospital database system. Patients who did not have a diagnostic sample drawn during the hospital stay were eligible to be included in the group of control-patients. Among them, patients who did not have a clinical sign of systemic infection and antibiotic prescriptions during the hospital stay were included in the group of control-patients. For each case-patient two control-patients admitted on the same day and in the same unit were selected.

All patients included in the study were followed from admission to discharge or in-hospital death. For each study patient, the following variables were collected: gender, age, germs isolated, resistance profile, underlying comorbidities, diagnosis at admission, interventions related to patient care such as surgical intervention and invasive procedures, length of stay (LOS), date of BSI onset, in-hospital mortality and antibiotics prescribed empirically.

Definitions {#sec009}
-----------

A BSI was suspected in the presence of fever (\> = 38°C), hypothermia (\<36°C) and other signs of systemic inflammatory response syndrome as detailed in the WHO guideline of the Integrated Management of Childhood Illness \[[@pone.0143729.ref015]\]. A blood sample was drawn from all inpatients with a suspected BSI. A BSI was defined by the presence of a bacterial strain recovered from blood samples. The infection was considered as hospital acquired if bacterial strain was recovered from blood samples drew at least 48h after the admission of patients and at least 72h after admission of neonates (aged between 1--28 days of life). BSI was considered as community-acquired if bacterial strain was recovered from blood samples drew within the 48h after admission (72h for neonates) and if the patient was not referred from another hospital, otherwise the infection was considered as hospital-acquired.

BSI was defined as ESBL-positive when the blood sample yielded an ESBL-producing *Enterobacteriaceae* and ESBL-negative when the strain isolated was an *Enterobacteriaceae* susceptible to beta-lactams.

Antibiotic therapy was defined as empirical if prescribed initially before susceptibility test results were available. Empirical antibiotic therapy was considered inadequate when the initial antibiotic drug prescribed was not active against the pathogen causing the infection.

Microbiological methods {#sec010}
-----------------------

*Enterobacteriaceae* strains were identified with API 20E strips (bioMérieux, Marcy l'Etoile, France). Minimum inhibitory concentration was not determined to define drug activity. Susceptibilities against antimicrobial agents and the ESBL production was routinely detected by the double disc diffusion method using antibiotic discs of cefepime, cefotaxime and ceftazidime placed at a distance of 30 mm around a disc of clavulanic acid as recommended by the Antibiogram Committee of the French Microbiology Society \[[@pone.0143729.ref016]\].

Statistical analysis {#sec011}
--------------------

Continuous variables were compared using Wilcoxon rank sum test or Student's t test if appropriate. In case of non-homogeneity of variances, the 2-tailed test was done by default and the Welch correction was applied. Fisher's exact test was used for the comparison of categorical variables. To evaluate risk factors to acquire an ESBL-E BSI 2 multivariate models were tested using a backward stepwise logistic regression analysis including all variables with a p-value less than 0.20 in the univariate analysis. Patients with ESBL-positive BSI were compared with patients with ESBL-negative BSI in model 1 then, compared with control-patients (uninfected patients) in model 2. A multivariate analysis using a backward stepwise logistic regression analysis was also performed to assess the risk factors for fatal outcomes. P value less than 0.05 was considered as significant in the whole analysis.

A multistate model was used to estimate the excess LOS attributable to ESBL production \[[@pone.0143729.ref017],[@pone.0143729.ref018]\]. The occurrence of BSI (whether ESBL-positive or ESBL-negative) was the time-dependent exposure, while discharge (alive or dead) was the study endpoint ([Fig 1](#pone.0143729.g001){ref-type="fig"}). Non-parametric estimation of transition probabilities between states was performed using the Aalen-Johansen estimator \[[@pone.0143729.ref018]--[@pone.0143729.ref020]\]. The mean difference in LOS was computed for each day of the interval, as the difference between the estimated LOS given the intermediate state had been reached or not up to that day. The excess LOS attributable to ESBL production was the difference between LOS due to ESBL-positive and LOS due to ESBL-negative BSI. When assessing the LOS due to ESBL-positive BSI, patients with ESBL-positive BSI were compared to patients who did not experience a BSI during hospital stay and patients with ESBL-negative BSI but the latter were administratively censored from the date of their infection. Likewise, patients with ESBL-positive BSI were administratively censored when assessing the LOS due to ESBL-negative BSI. Standard errors and confidence intervals were calculated by 500 bootstrap resampling runs.

![Multistate modelling used for the excess length of stay analysis.\
Patients enter the model in state 1 at hospital admission, make a transition into state 2 at the time of infection (whether ESBL-positive or ESBL-negative BSI) then move to the absorbing state 3 at the time of discharge or death. Patients who do not experience an infection during their hospital stay move directly from state 1 to state 3. **BSI:** Bloodstream infection. **ESBL-positive**: *Enterobacteriaceae* producing extended spectrum beta-lactamase. **ESBL-negative**: *Enterobacteriaceae* susceptible to beta-lactams.](pone.0143729.g001){#pone.0143729.g001}

To assess the independent effect of ESBL-positive and ESBL-negative BSI on LOS, they were evaluated as time-dependent covariates using multivariate Cox regression analysis to estimate the end-of-LOS hazard ratio (HR). Variables for adjustment included age, newborn, malnutrition, sickle cell disease and mechanical ventilation.

LOS analysis was performed using R, version 2.15.3, an open-source language for statistical computing and graphics. All other analysis were performed using Stata software, release 13.0.

Ethical considerations {#sec012}
----------------------

The medical advisory board of Albert Royer Hospital approved this retrospective study. All data collected were anonymized prior to analysis.

Results {#sec013}
=======

Characteristics of the study patients {#sec014}
-------------------------------------

During the study period, blood samples were drawn from 1,800 patients with suspected BSI of which 173 (10%) yielded a bacterial strain. Contaminants were found in 36.8% of blood cultures ([Fig 2](#pone.0143729.g002){ref-type="fig"}). BSI was hospital-acquired (HA) in 81.5% of cases (n = 141). The epidemiology of bacterial strains involved in BSI cases described in [table 1](#pone.0143729.t001){ref-type="table"} showed that *Enterobacteriaceae* was mainly recovered from blood cultures. Besides, ESBL-E was the major resistant strain isolated and was more frequent in hospital than community-acquired BSI (59.6% versus 34.4, p = 0.010) ([Table 1](#pone.0143729.t001){ref-type="table"}).

![Flow diagram of study patients' selection.\
(1): Strains associated with community-acquired BSI: *Enterobacteriaceae* (21), *Pseudomonas aeruginosa (*2), *Staphylococcus spp* (6), *Streptococcus spp (3)*. (2): Strains associated with hospital-acquired BSI: *Pseudomonas aeruginosa* (6), *Staphylococcus aureus* (22), *Streptococcus* spp (3).](pone.0143729.g002){#pone.0143729.g002}

10.1371/journal.pone.0143729.t001

###### Characteristics of the study patients with community and hospital-acquired bloodstream infections (n = 173 patients).

![](pone.0143729.t001){#pone.0143729.t001g}

  Characteristics                 TOTAL (n = 173)   Source of the infection   P value      
  ------------------------------- ----------------- ------------------------- ------------ -------
  **Demographics**                                                                         
  Male Sex                        91(52.6)          71(50.3)                  20(62.5)     0.243
  Mean, years (range)             3.3(0--17)        3.3 (0--16)               3.6(0--17)   0.214
  **Unit of hospitalization**                                                              
  Pediatrics                      108(62.4)         89(63.1)                  19(59.4)     0.687
  Surgery                         29(16.8)          22(15.6)                  7(21.9)      0.687
  Neonatology                     36(20.8)          30(21.3)                  6(18.7)      0.687
  **Pathogens isolated, n (%)**                                                            
  Enterobacteriaceae              131(75.7)         110 (78.1)                21(65.6)     0.182
  Pseudomonas aeruginosa          8(4.6)            6(4.2)                    2(6.2)       0.182
  Staphylococcus aureus           28(16.2)          22(15.6)                  6(18.7)      0.182
  Streptococcus                   6(3.5)            3(2.1)                    3(9.4)       0.182
  **Resistant strains**                                                                    
  ESBL-E                          95(54.9)          84(59.6)                  11(34.4)     0.010
  MRSA                            2(1.1)            2(1.4)                    0(0)         

**ESBL-E:** Extended-spectrum beta-lactamase producing *Enterobacteriaceae*

**MRSA**: Methicillin-resistant *Staphylococcus aureus*

The overall incidence rate of HA-BSI caused by ESBL-E strains was of 1.52 cases / 1000 patient-days (95% CI: 1.2--5.6 cases per 1000 patient-days). ESBLs were produced by 88% of *Enterobacter spp* isolates, 82% of *Klebsiella spp* isolates and 58.3% of *E*.*coli* isolates ([Table 2](#pone.0143729.t002){ref-type="table"}).

10.1371/journal.pone.0143729.t002

###### Proportion of ESBL producing *Enterobacteriaceae* among hospital-acquired BSI (n = 110 patients).
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  Pathogens                Number of isolates n (%)   ESBL-E [^a^](#t002fn001){ref-type="table-fn"} n (%)
  ------------------------ -------------------------- -----------------------------------------------------
  *Enterobacter spp*       50(45.5)                   44(88.0)
  *Klebsiella spp*         40(36.4)                   33(82.5)
  *Escherichia coli*       12(10.9)                   7(58.3)
  *Salmonella spp*         4(3.6)                     0
  *Citrobacter freundii*   2(1.8)                     0
  *Proteus mirabilis*      2(1.8)                     0
  **Total**                **110 (100.0)**            **84(76.4)**

^a^ Proportion of ESBL strains per species (percentages were calculated by row)

Characteristics of case-patients (n = 110) and controls (n = 220) are detailed in [table 3](#pone.0143729.t003){ref-type="table"}. Cases were constituted of 84 patients with ESBL-positive BSI and 26 patients with ESBL-negative BSI ([Table 3](#pone.0143729.t003){ref-type="table"}).

10.1371/journal.pone.0143729.t003

###### Factors associated with ESBL-E BSI: results of univariate analyses comparing ESBL-positive BSI with ESBL-negative BSI (model 1) and ESBL-positive BSI with control-patients (model 2).
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  Variable, n (%)                ESBL+ (n = 84)   ESBL--(n = 26)   Controls (n = 220)   P-value 1[^a^](#t003fn001){ref-type="table-fn"}   P-value 2[^b^](#t003fn002){ref-type="table-fn"}
  ------------------------------ ---------------- ---------------- -------------------- ------------------------------------------------- -------------------------------------------------
  **Demographics**                                                                                                                        
  Male                           44(52.4)         14(53.8)         111(50.4)            1                                                 0.798
  Mean age, years                2.5              4.4              3.7                  0.021                                             0.016
  Newborn                        27(32.1)         2(7.7)           48(21.9)             0.012                                             0.074
  Prematurity                    7(8.3)           2(7.7)           4(1.8)               1                                                 0.012
  **Comorbidity**                                                                                                                         
  Sickle cell disease            28(33.3)         3(11.5)          7(3.2)               0.044                                             \<0.0001
  Malnutrition                   32(38.1)         4(15.4)          9(4.1)               0.034                                             \<0.0001
  Severe anemia                  16(19.0)         8(30.8)          31(14.1)             0.276                                             0.291
  **Diagnosis at admission**                                                                                                              
  Severe malaria                 11(13.1)         4(15.4)          34(15.4)             0.750                                             0.719
  Gastroenteritis                4(4.8)           8(30.8)          65(29.5)             0.0009                                            \<0.0001
  Respiratory disease            25(29.8)         8(30.8)          40(18.2)             1                                                 0.041
  Cardiovascular disease         3(3.5)           1(3.8)           4(1.8)               1                                                 0.399
  Meningitis                     5(5.9)           1(3.8)           7(3.2)               1                                                 0.323
  Ear, nose and throat disease   10(11.9)         3(11.5)          24(10.9)             1                                                 0.839
  **Invasive procedure**                                                                                                                  
  Surgical intervention          15(17.8)         5(19.2)          36(16.4)             1                                                 0.734
  Parenteral nutrition           24(28.6)         10(38.5)         22(10.0)             0.343                                             \<0.0001
  Mechanical ventilation         53(63.1)         14(38.5)         32(14.5)             0.040                                             \<0.0001
  Catheter                       45(53.6)         11(42.3.)        16(7.3)              0.373                                             \<0.0001
  Blood transfusion              16(19.0)         3(11.5)          12(5.5)              0.554                                             0.0006

^a^ P-value 1 refer to model 1 in which ESBL-positive BSI are compared with ESBL-negative BSI

^b^ P-value 2 refer to model 2 in which ESBL-positive BSI are compared with control-patients (uninfected patients)

Risk factors for ESBL-E BSI {#sec015}
---------------------------

Univariate analysis presented in [table 3](#pone.0143729.t003){ref-type="table"} showed that patients with ESBL-positive BSI were significantly younger than patients with ESBL-negative BSI (2.5 years versus 4.4 years, p = 0.021). Besides, they were more likely to suffer from sickle cell disease (33.3% versus 11.5%, p = 0.044), to be malnourished (38.1% versus 15.4%, p = 0.034) and to be under mechanical ventilation (63.1% versus 38.5%, p = 0.040) than ESBL-negative BSI. Same differences were observed when comparing patients with ESBL-positive BSI with control-patients ([Table 3](#pone.0143729.t003){ref-type="table"}). Additional factors related to healthcares, such as parenteral nutrition and the use of catheter, were significantly more frequent in patients with ESBL-positive BSI than in control-patients ([Table 3](#pone.0143729.t003){ref-type="table"}). Multivariate analyses performed in model 1 and model 2 indicated that independent risk factors for ESBL-E BSI acquisition were: to be a newborn (OR = 11.4, 95%CI: 5.7--198, p = 0.041), having a sickle cell disease (OR = 3.1, 95%CI: 2.3--4.9, p\<0.0001), being malnourished (OR = 2.0, 95%CI: 1.7--2.6, p\<0.0001), and being under mechanical ventilation (OR = 3.5, 95%CI: 2.7--5.3, P\<0.0001) ([Table 4](#pone.0143729.t004){ref-type="table"}).

10.1371/journal.pone.0143729.t004

###### Risk factors for ESBL-E BSI acquisition: results of multivariate analyses.
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  Variable including in models   Initial Model 1[^a^](#t004fn002){ref-type="table-fn"}   Initial Model 2[^b^](#t004fn003){ref-type="table-fn"}   Final Model 1[^a^](#t004fn002){ref-type="table-fn"}   Final Model 2[^b^](#t004fn003){ref-type="table-fn"}                                 
  ------------------------------ ------------------------------------------------------- ------------------------------------------------------- ----------------------------------------------------- ----------------------------------------------------- ---------- ------ ----------- ----------
  Newborn                        0.012                                                   0.074                                                   2.8                                                   1.9--60                                               \<0.0001   11.4   5.7--198    0.041
  Prematurity                    \-                                                      0.012                                                   \-                                                    \-                                                    \-         4.7    2.5--41.8   0.027
  Sickle cell disease            0.044                                                   \<0.0001                                                3.8                                                   2.3--10.3                                             0.002      3.1    2.3--4.9    \<0.0001
  Malnutrition                   0.034                                                   \<0.0001                                                2.8                                                   1.9--5.3                                              \<0.0001   2.0    1.7--2.6    \<0.0001
  Parenteral nutrition           \-                                                      \<0.0001                                                \-                                                    \-                                                    \-         9.6    4.9--98     0.039
  Mechanical ventilation         0.025                                                   \<0.0001                                                6.1                                                   3.1--228.9                                            0.044      3.5    2.7--5.3    \<0.0001
  Catheter                       0.170                                                   \<0.0001                                                                                                                                                                       4.0    2.9--6.7    \<0.0001
  Blood transfusion              0.149                                                   0.0006                                                                                                                                                                                            

Multivariate analyses were performed using a backward stepwise logistic regression including variables with a p \<0.20 in the univariate analyses ([Table 3](#pone.0143729.t003){ref-type="table"}). P-value \<0.05 was considered as statistically significant.

^a^**Model 1**: ESBL-positive BSI versus ESBL-negative BSI

^b^**Model 2**: ESBL-positive BSI versus control-patients (uninfected patients)

Antimicrobial prescriptions {#sec016}
---------------------------

All patients with BSI received an empirical antimicrobial therapy, which was mainly a third generation cephalosporin (90%). Initial antibiotic therapy was inadequate to treat 79.1% of BSI infections (n = 87). Inadequate initial antibiotic therapy (IIAT) was more frequent in ESBL-positive BSI than in ESBL-negative BSI (94.2% versus 5.7%, p\<0.0001). Besides, patients who received an IIAT were more likely to have a fatal outcome (92% versus 8%, p = 0.0019) and a longer hospital stay (22.9 days versus 14.2 days, p = 0.013) than patients who received an adequate empirical therapy.

Fatal outcomes {#sec017}
--------------

Fifty patients with a BSI caused by an *Enterobacteriaceae* died during the study period (45.4%). The case-fatality rate was significantly higher in ESBL-positive BSI (54.8%) than in ESBL-negative BSI (15.4%) (p\<0.001). Univariate analysis showed that fatal outcomes more frequently occurred in young children, in newborns and patients being under mechanical ventilation ([Table 5](#pone.0143729.t005){ref-type="table"}). Additionally, patients who died were more likely to have an ESBL-E BSI and to receive an inadequate initial antibiotic therapy than patients who survived. In the multivariate analysis, ESBL production remained the significant independent risk factor for death (OR = 2.9, 95% CI: 1.8--7.3, p = 0.001).

10.1371/journal.pone.0143729.t005

###### Factors associated with fatal outcomes: results of univariate and multivariate analysis.
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                                              Fatal outcome   Univariate analysis   Multivariate analysis[\*](#t005fn001){ref-type="table-fn"}                                          
  ------------------------------------------- --------------- --------------------- ------------------------------------------------------------ ----------- -------- ----- ----------- -------
  **Demographics**                                                                                                                                                                      
  Male                                        24(48)          28(46.7)              1.1                                                          0.5--2.2    1                          
  Mean age, years                             1.5             4.2                                                                                            0.0003                     
  Newborn                                     19(38)          10(16.7)              3.1                                                          1.3--7.3    0.016                      
  Prematurity                                 6(12)           3(5)                  2.6                                                          0.7--9.9    0.295                      
  **Comorbidity**                                                                                                                                                                       
  Sickle cell disease                         13(26)          18(30)                0.8                                                          0.3--1.9    0.676                      
  Malnutrition                                18(36)          18(30)                1.3                                                          0.6--2.9    0.545                      
  Severe anemia                               10(20)          14(23.3)              0.8                                                          0.3--2.0    0.817                      
  **Diagnosis at admission**                                                                                                                                                            
  Severe malaria                              7(14)           8(13.3)               1.1                                                          0.4--3.1    1                          
  Gastroenteritis                             1(2)            11(18.3)              0.1                                                          0--0.6      0.006                      
  Respiratory disease                         19(38)          14(23.3)              2.0                                                          0.9--4.6    0.101    3.0   1.4--17.6   0.093
  Cardiovascular disease                      2(4)            2(3.3)                1.2                                                          0.2--7.1    1                          
  Meningitis                                  5(10)           1(1.7)                6.5                                                          0.9--1.2    0.090                      
  Ear, nose and throat disease                6(12)           7(11.7)               1.0                                                          0.3--3.1    1                          
  **Invasive procedure**                                                                                                                                                                
  Surgical intervention                       7(14)           13(21.7)              0.6                                                          0.2--1.6    0.332                      
  Parenteral nutrition                        12(24)          22(36.7)              0.5                                                          0.2--1.2    0.214                      
  Mechanical ventilation                      35(70)          28(46.7)              2.7                                                          1.2--5.8    0.019    6.5   2.9--34.4   0.098
  Catheter                                    27(54)          29(48.3)              1.2                                                          0.5--2.6    0.572                      
  Blood transfusion                           9(18)           10(16.7)              1.1                                                          0.4--2.9    1                          
  **ESBL Production**                         46(92)          38(63.3)              6.6                                                          2.2--20.0   0.0006   2.9   1.8--7.3    0.001
  **Inadequate initial antibiotic therapy**   46(92)          41(68.3)              5.3                                                          1.7--16.1   0.002                      

\*Multivariate analyses was performed using a backward stepwise logistic regression including variables with a p \<0.20 in the univariate analyses. P-value \<0.05 was considered as statistically significant.

Length of stay (LOS) {#sec018}
--------------------

The mean LOS for patients with ESBL-positive BSI and ESBL-negative BSI was 22.5 days (95%CI: 18-5-26. days) and 12.6 days (95%CI: 9.5--15.8 days) respectively (p\<0.0001). The results of the multistate model showed an excess LOS attributable to ESBL production of 4.3 days ([Table 6](#pone.0143729.t006){ref-type="table"}). Besides, ESBL-positive BSI significantly reduced hazard of discharge (dead or alive) after adjustment for confounding (HR = 0.07, \[95%CI, 0.04--0.12\]) and consequently prolonged LOS.

10.1371/journal.pone.0143729.t006

###### Estimation of the excess length of stay (LOS) and hazard ratios (HR) of end-of-LOS associated with ESBL-positive and ESBL-negative BSI.
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                                                                                End-of-LOS HR       
  ---------------------------------------------------------- ------------------ ------------------- -------------------
  ESBL-positive BSI [^a^](#t006fn002){ref-type="table-fn"}   5.1 (3.82--5.62)   0.18 (0.13--0.24)   0.07 (0.04--0.12)
  ESBL-negative BSI [^b^](#t006fn005){ref-type="table-fn"}   0.8 (0.74--1)      0.66 (0.44--0.99)   0.12 (0.07--0.21)

**CI**: confidence interval

^a^**Model A**: Excess LOS due to ESBL-positive BSI

Cases: ESBL-positive BSI (n = 84)

Controls: ESBL-negative BSI (n = 26) censored at time of infection + control-patients (uninfected patients) (n = 220)

^**b**^**Model B**: Excess LOS due to ESBL-negative BSI

Cases: ESBL-negative BSI (n = 26)

Controls: ESBL-positive BSI (n = 84) censored at time of infection + control-patients (uninfected patients) (n = 220)

Discussion {#sec019}
==========

Our study highlights an alarming rate of ESBL production among *Enterobacteriaceae* strains associated with BSI. In addition, a significant part of ESBL-E BSI was severe sepsis associated with fatal outcome and prolonged hospital stay. We have estimated an incidence rate of ESBL-E BSI of 1.52 cases / 1000 patient-days which is higher than those reported through the national surveillance of multidrug-resistant bacteria in France where ESBL-E rate is increasing dramatically since 2003 (0.054/1000 patients-days in 2012) \[[@pone.0143729.ref021],[@pone.0143729.ref022]\]. Besides, this ESBL-E incidence is higher than that previously reported in one African healthcare setting \[[@pone.0143729.ref002]\]. However, the paucity of studies on childhood ESBL-E BSI from Africa does not allow a thorough comparison. To our knowledge, our study is the only one on this topic in sub-Saharan Africa since a Tanzanian study published ten years ago that had much narrower scope \[[@pone.0143729.ref023]\].

The high rate of ESBL-E strains we have found should be interpreted with caution. Indeed, when an infection is first suspected in primary care settings antibiotic drugs are frequently prescribed without drawing any biological samples since microbiology laboratories are not available in these settings. Thus, patients admitted at hospital if no recovery is observed may receive antibiotic drugs, especially 3^rd^ generation cephalosporins, prior to the hospital admission. In contrast, when an infection was suspected in the hospital study, blood samples were drawn systematically before the initiation of the antibiotherapy. Antibiotic prescriptions prior to blood culture, also reported in another African country \[[@pone.0143729.ref002]\], may be a selection factor of resistant strains and may limit the detection of susceptible strains. Therefore, the overuse of antibiotic drugs prior to hospital admission may explain the low rate of positive blood cultures we found (10%) and may bias the proportion of ESBL strains. Antimicrobial therapy before hospital admission has already been reported as a major risk factor for ESBL-E acquisition \[[@pone.0143729.ref024]--[@pone.0143729.ref027]\]. Unfortunately, prescriptions prior to admission were not available in the patients' medical files and were not collected in our study.

The high incidence rate of ESBL-E BSI also raises the issue of the choice of 3^rd^ generation cephalosporins as systematic empirical treatment. Indeed, empirical antimicrobial therapy was found inadequate to treat the majority of BSI and was more frequent in ESBL-positive BSI than in ESBL-negative BSI. Reports about inadequate initial antibiotherapy in children in Africa are scarce. However, consistent with other studies, we demonstrated that inadequate initial antibiotic therapy (IIAT) was associated with increased case-fatality rate and prolonged hospital stay \[[@pone.0143729.ref028]--[@pone.0143729.ref034]\]. Therefore, knowledge of the local bacterial epidemiology and their susceptibility patterns is crucial for clinicians and should guide empirical antibiotic therapy prescription. Beta-lactams could therefore be used after determination of antibiotic drug activity. Furthermore, since genes encoding ESBL and other resistance to commonly used antibiotics such as fluoroquinolones are often on the same mobile DNA element, the multidrug-resistant phenotype of ESBL-producing bacteria limits effective therapeutic options and causes a delay in initiating adequate antimicrobial therapy \[[@pone.0143729.ref028],[@pone.0143729.ref029],[@pone.0143729.ref032]\]. In resource-poor countries, some factors such as the lack of functional microbiology laboratory for pathogens detection may hamper the prompt initiation of adequate therapy crucial to treat BSI. When microbiology laboratory exists, mostly in referral tertiary care hospitals, bacteriological results are not available quickly enough to adjust empirical therapy. Additionally, expensive effective therapies to treat ESBL-E infections such as carbapenems are mostly unavailable or beyond the financial reach of most patients living in Senegal.

To our knowledge, risk factors for ESBL-BSI acquisition in children have not been assessed previously in lower-middle-income countries. Using a case-case-control study, we identified several risk factors specifically related to ESBL-E BSI including some related to the underlying disease and others to healthcare procedures. The case-case-control study design is considered to be the most appropriate method when assessing risk factors specific of antibiotic-resistant pathogen acquisition without introducing a potential selection bias \[[@pone.0143729.ref035]--[@pone.0143729.ref038]\]. Patients who suffered from sickle cell disease or malnutrition were found at risk to acquire an ESBL-E BSI. We also found that being under mechanical ventilation was a risk factor for ESBL-E BSI suggesting a cross-transmission of pathogens. Newborns were also identified as patients at risk to acquire an ESBL-E BSI. This may be explained by their immature immune systems and the overly intensive cares they received, especially for pre-term or low birthweight neonates. ESBL strains may be transmitted from mothers to newborns during delivery; however further studies are required to determine the association between the mother's colonization and the acquisition of an ESBL-infection by neonates. Poor conditions of clinical cares could also increase this risk. Thus, particular attention should be given to newborns during and after delivery, and during nursing cares. To prevent the transmission of ESBL isolates, training of healthcare workers on standard precautions, such as hand hygiene, should be reinforced as recommended \[[@pone.0143729.ref039]--[@pone.0143729.ref041]\]. Infection control programs particularly focused on hand hygiene was showed effective to decrease the rate of Methicillin-resistant *Staphylococcus aureus* strains \[[@pone.0143729.ref039]\]. However additional control measures specifically targeting ESBL strains should be implemented. These measures should focus on the management of excreta since the main reservoir of *Enterobacteriaceae* strains is the human digestive tract.

We also showed a prolonged LOS of 4.3 days attributable to ESBL production. To estimate this excess LOS we used a multistate model, a statistical approach which treats the occurrence of BSI as time-dependent and takes into account competing events thereby avoiding the time-dependent bias inherent in other commonly used statistical methods \[[@pone.0143729.ref017],[@pone.0143729.ref020],[@pone.0143729.ref042]--[@pone.0143729.ref045]\]. Indeed, if the occurrence of the BSI is not explicitly modeled as time-dependent, its impact on length of stay and consequently on hospital costs will inevitably be overestimated \[[@pone.0143729.ref043],[@pone.0143729.ref044],[@pone.0143729.ref046]\]. Our study confirms that multistate modelling is a suitable approach since we found an excess LOS attributable to ESBL production of 4.3 days while taking into account time of infection compared to an excess LOS of 9.9 days using standard technics.

The economic impact of ESBL-E BSI was not the purpose of the present study, however it has been demonstrated elsewhere that the excess length of stay is one main driver of hospital costs and that hospital bed-day cost could represent almost 60% of their total cost \[[@pone.0143729.ref047],[@pone.0143729.ref048]\]. Therefore, using the average bed-day hospital cost we estimated from the patient perspective an extra-cost of 75 euros due to the excess LOS attributable to ESBL-E production. This additional cost is substantial given Senegal's LMIC status where it is close to the mean monthly salary of 87 euros \[[@pone.0143729.ref049]\]. This estimated financial burden of ESBL-E BSI would be substantially higher if antibiotic therapy were included, especially if this therapy consisted of the costly carbapenems, which remain the only antibiotic therapy effective to treat ESBL-E infections.
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